Lung Transplantation for Pleuroparenchymal Fibroelastosis

Pleuroparenchymal fibroelastosis (PPFE), a new disease entity associated with interstitial pneumonia, is characterized by fibrosis and elastosis involving the pleura and subpleural lung parenchyma, predominantly in the upper lobe. As the awareness of this disease entity has increased, many studies have revealed the prevalence and incidence, clinical and pathological characteristics, and disease course of PPFE. Patients with PPFE reportedly have several unique clinical characteristics-including an extremely low body mass index with a slender body and chest wall deformity, known as flat chest. As this disease progresses, shrinking of the lungs often causes life-threatening complications, such as pneumothorax, and associated air leak syndrome. Lung transplantation is considered the only effective treatment for patients with advanced PPFE; however, little is known about the influences of the characteristics of PPFE on the outcome of lung transplantation. This review focuses on the unique clinicopathologic characteristics of PPFE and associated outcomes of lung transplantation for these patients.

Automated summary

Pleuroparenchymal fibroelastosis (PPFE) is a new disease entity associated with interstitial pneumonia, characterized by fibrosis and elastosis predominantly in the upper lobe, leading to lung shrinkage and life-threatening complications. Patients usually have extremely low body mass index and flat chest. Lung transplantation is considered the only effective treatment for advanced PPFE patients.